A kind of external aerosol and preparation method thereof

By adding permeability promoters and film-forming agents to the Keriboro aerosol, a transparent and smooth film is formed, which solves the viscosity and inaccurate dose of traditional ointments, and achieves rapid drying and high penetration of aerosols , suitable for children and improves clinical compliance and bioavailability.

CN116139085BActive Publication Date: 2024-11-08SHENZHEN BEIMEI PHARM CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310186035.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-01
Publication Date
2024-11-08
Estimated Expiration
2043-03-01

AI Technical Summary

Technical Problem

The existing Keliborole ointment has a viscous feeling, difficulty in cleaning, inaccurate dosage and greasy skin when used, and is especially not suitable for children and has poor clinical compliance.

Method used

A topical aerosol was developed, containing kerborole, solvent, permeability agent and film forming agent. By spraying, a transparent and smooth non-adhesive film is formed to improve the absorption and administration accuracy of drug, and the use of butyl methacrylate Film-forming agents such as -(2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer and permeation promoters such as propylene glycol, combined with HFA or HFO propellant, the preparation process is simple.

Benefits of technology

It achieves rapid drying, good permeability and stability of aerosols, is suitable for children, overcomes the inconvenience and inaccurate dosage of traditional creams, and improves clinical compliance and bioavailability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GHA0000006326290000041
    Figure GHA0000006326290000041
  • Figure GHA0000006326290000051
    Figure GHA0000006326290000051
  • Figure GHA0000006326290000052
    Figure GHA0000006326290000052
Patent Text Reader

Abstract

The present application relates to the field of external medicine, and specifically discloses an external aerosol and a preparation method thereof. The external aerosol comprises crisaborole, a solvent, a penetration enhancer, a film former and a propellant; in terms of weight percentage, crisaborole 0.1% to 5.0%, solvent 5% to 40%, penetration enhancer 0.5% to 5.0%, film former 0.1% to 5.0%, and propellant 50% to 90%. It can be dried quickly during use and form a transparent, smooth, non-sticky film on the skin. It is easy to use, does not feel greasy, and has good stability. Compared with creams, it has the characteristics of accurate dosage, good skin penetration performance, high bioavailability, and excellent clinical compliance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of external medicine, and more specifically, to an external aerosol and a preparation method thereof. Background Art

[0002] Atopic dermatitis (AD) is a common disease worldwide that can be found at any age, usually before the age of five. The typical manifestations are divided into three stages: infancy, childhood and adulthood, and acute, subacute and / or chronic skin manifestations can occur in each stage.

[0003] Atopic dermatitis lasts for a long time, presents a chronic process, and recurrent attacks, which may be accompanied by asthma or allergic rhinitis. The etiology and pathogenesis of allergic dermatitis have not yet been fully clarified. It is generally believed that it is caused by the stimulation and interaction of various internal and external factors, including genetic factors, immune factors, and environmental factors. At present, the incidence of allergic dermatitis in developed countries remains at 10-20%, and is showing an increasing trend year by year.

[0004] Clisborole is a phosphodiesterase 4 (PDE4) inhibitor. PDE4 is an enzyme involved in controlling the activity of inflammatory cells. PDE4 participates in the production of inflammatory factors such as IL-4 / 5 / 10 / 13 and prostaglandin PGE2 in inflammatory cells by controlling the degradation of cyclic adenosine monophosphate. It exerts its effects by inhibiting the activity of PDE4 and improving the body's inflammatory response.

[0005] Currently, crisaborole is used in the form of an ointment, but creams are traditional drug preparations, which are sticky and uncomfortable to use, especially when used by young children, who can easily wipe off the drug, and cannot achieve the therapeutic effect of the drug. In addition, according to the characteristics of atopic dermatitis, long-term continuous administration is required. After the cream is administered, the skin surface is greasy, and it is difficult to clean after contact with clothing, etc., and the clinical compliance is poor. In addition, the dosage of the cream is difficult to determine when it is used, and there is a risk of overdose. Summary of the invention

[0006] The present invention provides an external aerosol and a preparation method thereof, which can be dried quickly when used and form a transparent, smooth, non-sticky film on the skin, which is easy to use, non-greasy, and has good stability. Compared with creams, it has the characteristics of accurate dosage, good skin permeability, high bioavailability, and excellent clinical compliance.

[0007] In a first aspect, the present disclosure provides an external aerosol, comprising crisaborole, a solvent, a penetration enhancer, a film-forming agent, and a propellant;

[0008] Calculated by weight percentage, the composition comprises 0.1% to 5.0% of crisaborole, 5% to 40% of solvent, 0.5% to 5.0% of penetration enhancer, 0.1% to 5.0% of film former and 50% to 90% of propellant.

[0009] Clisborole has accumulated a library of boron-containing compounds with diverse structures. The compound library provides a material basis for new anti-allergic dermatitis drugs. It is convenient and quick to use, and has excellent clinical compliance. The addition of penetration enhancers and film-forming agents allows the aerosol to quickly form a film to protect the skin, thereby improving clinical compliance. In addition, the prepared Clisborole aerosol has good stability and skin permeability, making it more suitable for children.

[0010] Preferably, the film-forming agent is one or more of butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer, polyethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate chloride, acrylic resin, polyvinyl pyrrolidone, polyamide, hydroxypropyl methylcellulose, and polyvinyl alcohol.

[0011] Preferably, the external aerosol comprises, by weight percentage, 0.1% to 5.0% of crisaborole, 5% to 40% of solvent, 0.5% to 5.0% of penetration enhancer, 0.1% to 5.0% of film former, and 50% to 90% of propellant.

[0012] Preferably, the external aerosol comprises, by weight percentage, 0.1% to 3.0% of crisaborole, 10% to 40% of solvent, 0.5% to 4.0% of penetration enhancer, 0.1% to 3.0% of film former, and 60% to 80% of propellant.

[0013] Preferably, the penetration enhancer is one or more selected from propylene glycol, medium chain triglycerides (GTCC), diisopropyl adipate, Transcutol P, polyethylene glycol, isopropyl myristate, and phenoxyethanol.

[0014] Preferably, the propellant is one or more of HFA, HFO and butane.

[0015] Preferably, the solvent is one or more of water, ethanol, isopropanol and glycerol.

[0016] Preferably, other pharmaceutical excipients are also included, and the other pharmaceutical excipients are one or more of antioxidants and metal chelators.

[0017] Preferably, the topical aerosol is used for the local treatment of mild to moderate allergic dermatitis.

[0018] In a second aspect, the present disclosure provides an external aerosol and a preparation method thereof, comprising the following preparation steps:

[0019] S1: premixed solution: stir the prescribed amount of the solvent and the penetration enhancer evenly, add the film-forming agent and the other excipients, dissolve them completely to obtain a clear solution, then add the crisaborole, stir and dissolve;

[0020] S2: filling: add the premixed solution into the tank, install the valve system and seal it, pour the propellant into the pressure-resistant container, and obtain the external aerosol after the air-tightness inspection is passed.

[0021] The topical aerosol can be dried quickly when used and form a transparent, smooth, non-sticky film on the skin. It is easy to use, not greasy, and has good drug absorption. It has excellent clinical compliance, is easy and quick to use, solves the problem of children's difficulty in use or poor use feeling, has a simple preparation process, and is suitable for industrial production.

[0022] In summary, this application has the following beneficial effects:

[0023] 1. The film-forming agent and penetration enhancer added in the present application enable the aerosol to form a thin film on the skin surface by spraying on the skin surface during use, and also promote the absorption of crisaborole by the skin epidermis, thereby improving the medicinal effect;

[0024] 2. The topical aerosol in the present application can be dried quickly when used and form a transparent, smooth, non-sticky film on the skin, which is easy to use, does not feel greasy, and has good drug absorption;

[0025] 3. The preparation method of the present application is relatively simple, the topical aerosol has excellent clinical compliance, is easy and quick to use, solves the problem of children having difficulty using it or having a poor sense of use, and the preparation process is simple and suitable for industrial production.

[0026] It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not intended to limit the scope of protection of the present disclosure. DETAILED DESCRIPTION

[0027] The present application is further described in detail below in conjunction with the examples. It is particularly noted that if no specific conditions are specified in the following examples, the experiments are carried out according to conventional conditions or the conditions recommended by the manufacturer. Unless otherwise specified, the raw materials used in the following examples can be obtained from common commercial sources.

[0028] The solvent in the embodiment is ethanol, the penetration enhancer is propylene glycol, isopropyl myristate, Transcutol P, polyethylene glycol 400, diisopropyl adipate, the film-forming agent is polyethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate chloride (Eudragit RS100), butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer (Eudragit E 100), Oleocraft HP 31, the propellant is HFA, HFO, and the antioxidant BHT is added to some aerosols. The prepared crisaborole aerosols are all transparent and colorless solutions, and the stability tests at room temperature and 40°C for 2 weeks and 4 weeks show no change in properties and stable properties.

[0029] Example

[0030] Example 1

[0031] Clisborole aerosol prescription:

[0032] Raw materials content% Clisborole 1.0 Ethanol 17.0 Propylene glycol 1.0 EudragitRS100 1.0 HFA 80

[0033] Preparation process: Add the prescribed amount of ethanol and propylene glycol into a container, add polyethyl acrylate-methyl methacrylate-methacrylate trimethylaminoethyl chloride Eudragit RS100, add crisaborole after complete dissolution, stir evenly, add the solution into the tank, install the valve system and seal it, and pour HFA into the pressure-resistant container to obtain.

[0034] Embodiment 2:

[0035] Clisborole aerosol prescription:

[0036]

[0037]

[0038] Preparation process: Add the prescribed amount of ethanol and propylene glycol to a container, add BHT to dissolve, then add polyethyl acrylate-methyl methacrylate-methacrylate trimethylaminoethyl chloride Eudragit RS100, add crisaborole after complete dissolution, stir evenly, add the solution to the tank, install the valve system and seal it, and pour HFA into the pressure-resistant container to obtain.

[0039] Embodiment 3:

[0040] Clisborole aerosol prescription:

[0041] Raw materials content% Clisborole 2.0 Ethanol 33.5 Isopropyl myristate 0.5 TranscutolP 2.5 Eudragit E100 1.5 HFA 60

[0042] Preparation process: Add the prescribed amount of ethanol, isopropyl myristate and Transcutol P into a container, add butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer Eudragit E 100, add crisaborole after complete dissolution, stir evenly, add the solution into the tank, install the valve system and seal it, and pour HFA into the pressure-resistant container to obtain.

[0043] Embodiment 4:

[0044] Clisborole aerosol prescription:

[0045]

[0046]

[0047] Preparation process: Add the prescribed amount of ethanol, isopropyl myristate and polyethylene glycol 400 into a container, add BHT to dissolve, then add butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer Eudragit E 100, add crisaborole after complete dissolution, stir evenly, add the solution into the tank, install the valve system and seal it, and pour HFA into the pressure-resistant container to obtain the product.

[0048] Embodiment 5:

[0049] Clisborole aerosol prescription:

[0050] Raw materials content% Clisborole 1.0 Ethanol 17.4 Diisopropyl adipate 0.75 TranscutolP 0.75 OleocraftHP31 0.1 HFO 80

[0051] Preparation process: Add the prescribed amount of ethanol, diisopropyl adipate and Transcutol P into a container, then add Oleocraft HP 31, add crisaborole after it is completely dissolved, stir evenly, add the solution into the tank, install the valve system and seal it, and pour HFO into the pressure-resistant container to obtain the product.

[0052] The method of using the crisaborole aerosol of the present application is: spray the aerosol evenly on the affected skin, the liquid medicine dries quickly to form a uniform transparent film, and it is used 1-2 times a day.

[0053] Comparative Example

[0054] Comparative Example 1:

[0055] The commercially available crisaborole cream (Sultanamine) was used as Comparative Example 1.

[0056] Comparative Example 2:

[0057] Clisborole aerosol prescription:

[0058] Raw materials content% Clisborole 0.04 Ethanol 7.46 Cyclomethicone 0.40 Isopropyl myristate 0.60 BHT 0.50 Eudragit E100 1.0 HFA 90

[0059] Preparation process: Add the prescribed amount of ethanol, isopropyl myristate and cyclomethicone into a container, add BHT to dissolve, then add butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer Eudragit E 100, add crisaborole after complete dissolution, stir evenly, add the solution into the tank, install the valve system and seal it, and pour HFA into the pressure-resistant container to obtain.

[0060] Comparative Example 3:

[0061] Clisborole aerosol prescription:

[0062] Raw materials content% Clisborole 2.0 Ethanol 29.9 TranscutolP 3.0 Polyethylene glycol 200 3.0 BHT 0.10 Eudragit E100 2.0 HFA 60

[0063] Preparation process: Add the prescribed amount of ethanol, polyethylene glycol 200 and Transcutol P into a container, add BHT to dissolve, then add butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer Eudragit E 100, add crisaborole after complete dissolution, stir evenly, add the solution into the tank, install the valve system and seal it, and pour HFA into the pressure-resistant container to obtain.

[0064] (1) Physical properties

[0065] The crisaborole aerosol and crisaborole cream prepared in Examples 1 to 4 and Comparative Examples 2 and 3 were used for comparison, and the macroscopic performance was as follows:

[0066] preparation Drying time Surface observation Example 1 52s Transparent solution, smooth film Example 2 55s Transparent solution, smooth film Example 3 68s Transparent solution, smooth film Example 4 48s Transparent solution, smooth film Example 5 38s Transparent solution, smooth film Comparative Example 1 >10min White paste Comparative Example 2 46s Transparent solution, smooth film Comparative Example 3 58s Transparent solution with sticky film

[0067] (2) Stability

[0068] The crisaborole aerosols prepared in Examples 1 to 4 and Comparative Examples 2 and 3 were stored at 25°C and 40°C, and their stability was examined after 2 weeks and 4 weeks, respectively. The results are as follows:

[0069] Properties:

[0070] On day 0, the crisaborole aerosols prepared in Examples 1 to 4 were all colorless transparent solutions. After 2 weeks and 4 weeks of storage, the properties of the above preparations did not change, and they were all colorless clear transparent solutions.

[0071] content:

[0072]

[0073]

[0074] purity:

[0075]

[0076] Conclusion: The aerosol of crisaborole has good stability. Under storage at 25°C and 40°C, it maintains a clear and transparent homogeneous system. The content purity remains basically stable. Therefore, the crisaborole aerosol prepared according to the present application has good stability.

[0077] (3) Permeability

[0078] The samples prepared in Example 2, Example 3, Example 4 and the commercially available crisaborole cream were subjected to an in vitro skin penetration (IVPT) experiment.

[0079] Experiment: Ex vivo human skin was used as a permeable membrane, and drugs were administered in the supply pool. Samples were taken from the receiving fluid every 3 hours to detect the content of crisaborole. After 24 hours of penetration, the cumulative amount of the drug in the epidermis and dermis was calculated as a proportion of the administered dose.

[0080] preparation 24h epidermal drug accumulation ratio Percentage of cumulative dermal drug volume in 24 hours Comparative Example 1 5.30% 6.36% Example 2 7.24% 9.97% Example 3 3.98% 9.74% Example 4 6.73% 8.84% Example 5 15.37% 9.97% Comparative Example 2 5.22% 5.04% Comparative Example 3 5.55% 4.64%

[0081] Conclusion: Clisborole is a topical drug that acts locally, and its target site is located in the dermis. The higher the proportion of the cumulative amount in the dermis to the dose, the higher the efficacy of the prescription in delivering the drug to the site of action and the higher the bioavailability of the drug. The efficacy of the example in delivering the drug to the site of action is higher than that of the commercially available Clisborole cream, and has higher bioavailability.

[0082] The above is only an exemplary embodiment of the present disclosure, but the protection scope of the present disclosure is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed in the present disclosure should be included in the protection scope of the present disclosure. Therefore, the protection scope of the present disclosure should be based on the protection scope of the claims.

Claims

1. An external aerosol, characterized in that: It consists of crisaborole, a solvent, a penetration enhancer, a film-forming agent and a propellant; or It is composed of crisaborole, solvent, penetration enhancer, film-forming agent, propellant and other pharmaceutical excipients; the other pharmaceutical excipients are one or more of antioxidants and metal chelating agents; In terms of weight percentage, crisaborole 0.1% to 5.0%, solvent 5% to 40%, penetration enhancer 0.5% to 5.0%, film former 0.1% to 5.0%, propellant 50% to 90%; Wherein, the film former is selected from butyl methacrylate-(2-dimethylaminoethyl) methacrylate-methyl methacrylate copolymer Eudragit E 100, polyethyl acrylate-methyl methacrylate-methacrylate trimethylaminoethyl chloride Eudragit RS 100, Oleocraft HP 31 acrylic resin; The penetration enhancer is selected from propylene glycol, diisopropyl adipate, Transcutol P, polyethylene glycol 400, and isopropyl myristate; The solvent is ethanol.

2. An external aerosol according to claim 1, characterized in that: The propellant is one or more of HFA, HFO and butane.

3. Use of an external aerosol according to any one of claims 1 to 2 in the preparation of an external aerosol for topical treatment of mild to moderate allergic dermatitis.

4. A method for preparing the external aerosol according to any one of claims 1 to 2, characterized in that: The method comprises the following preparation steps: S1: premixed solution: stir the prescribed amount of the solvent and the penetration enhancer evenly, add the film-forming agent and other excipients, dissolve them completely to obtain a clear solution, then add the crisaborole, stir and dissolve; S2: Filling: Add the premixed solution into the tank, seal it after installing the valve system, pour the propellant into the pressure-resistant container, and obtain the external aerosol after the air-tightness inspection is passed.

Citation Information

Patent Citations

  • Compositions and methods for dermal delivery of drugs

    CN101370453A

  • Preparation method and application of crisaborole topical slow-release liposome

    CN108210462A

  • Crisaborole external preparation as well as preparation method and application thereof

    CN113712977A

  • Spray-on formulations and methods for dermal delivery of drugs

    US20070189977A1

  • Methods and compositions for the treatment of granuloma annulare or subcutaneous inflammation and non-infection granulomatous diseases

    US20210212962A1